MicroRNA-based epigenetic approach to induce fetal hemoglobin
基于 MicroRNA 的表观遗传学方法诱导胎儿血红蛋白
基本信息
- 批准号:10212449
- 负责人:
- 金额:$ 30.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-13 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsANXA5 geneAddressAdultBiological AssayBlood Cell CountCD34 geneCell ProliferationCellsChildCholesterolClinicalComplete Blood CountContinuous InfusionCytosineDNADNA DamageDNA MethylationDNA Methyltransferase InhibitorDNA Modification MethylasesDNA Sequence AlterationDataDevelopmentDifferentiation AntigensDiseaseDoseEnzymesEpigenetic ProcessErythroidErythropoiesisFDA approvedFertilityFetal HemoglobinFlow CytometryFluorescenceFunctional disorderGYPA geneGene ExpressionGene Expression ProfilingGene Expression RegulationGene SilencingGenetic TranscriptionGenomeGenotypeGlobinGoalsHematopoiesisHemoglobinopathiesHumanHypermethylationHypoxiaIn VitroIndividualInfantInfusion proceduresKnowledgeLiquid substanceMYB geneMalignant NeoplasmsMeasuresMediatingMessenger RNAMethylationMicroRNAsMolecularMonitorMusMutationOncogenesPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacotherapyPhenotypePhysiologicalPlasmidsPlayPopulationPropidium DiiodidePublishingPumpRegulationResearchReticulocyte countRoleSeverity of illnessSickle CellSickle Cell AnemiaSpleenSubcutaneous InjectionsSwitch GenesSymptomsSystemTFRC geneTestingTherapeuticTherapeutic InterventionTissuesTransfectionTransferaseTreatment EfficacyUntranslated RNAWorkbasebench to bedsidebeta Globincancer cellchromatin modificationdrug developmentefficacy testingepigenetic silencingerythroid differentiationgamma Globinhydroxyureain vivoinnovationmethylation patternmouse modelnovelnovel therapeuticsoverexpressionpre-clinicalpreventprogenitorpromotersicklingside effectsmall moleculestem cellssubcutaneoustranscriptome sequencing
项目摘要
Project Abstract
This SHINE II application seeks to explore epigenetic mechanisms that control globin gene
regulation during erythropoiesis. The central hypothesis of this project is that that miR-29b
reverses the γ-globin to β-globin gene switch and induces HbF via modulation of DNA
methylation. Therapeutic interventions aimed at inducing HbF expression is an effective approach
for ameliorating the clinical symptoms of sickle cell disease (SCD) in adults and children.
Hydroxyurea is the only FDA-approved drug with proven efficacy for inducing HbF in patients with
SCD, but DNA methyltransferase (DNMT) inhibitors have shown promise as HbF inducers by
producing proximal γ-globin promoter DNA hypomethylation. However, DNMT inhibitors can
produce off-target side effects. Small non-coding microRNAs (miR) are attractive molecules for
targeting repressors of γ-globin gene expression and studies show that miR-29b inhibits DNA
methylation through direct targeting of the 3’ untranslated region of DNMT3A and DNMT3B. The
objective of this proposal is to test the efficacy of miR-29b as an HbF inducer. Our published work
shows that miR-29b is important for reactivating γ-globin transcription and HbF expression by
targeting MYB, a known repressor of γ-globin involved in mediating DNA methylation and gene
silencing. To test our central hypothesis, we will accomplish one specific aim to determine the
ability of miR-29b to mediate epigenetic changes in DNA methylation in the HBB locus and
reactivate γ-globin transcription and HbF expression during adult erythropoiesis. Sub-aim A will
explore the molecular effects of miR-29b on γ-globin regulation using an in vitro primary liquid
culture system to generate erythroid progenitors from peripheral blood mononuclear cells isolated
from individuals with SCD. These findings will compare to normal erythroid progenitors to validate
the ability of miR-29b to reactivate γ-globin transcription through proximal promoter DNA
methylation. Off-target effects mediated by miR-29b will be investigated by DNA mutation and
RNA-seq analyses. To define the role of miR-29b in reversing phenotype, erythroid progenitor
sickling under hypoxic conditions will be evaluated. Sub-aim B will establish the optimal dose of
miR-29b that mediates γ-globin reactivation and HbF induction in vivo using a preclinical Townes
SCD mouse model. This research highlights a novel miRNA-based epigenetic approach to induce
HbF to impact the discovery of new drugs to expand treatment options for SCD.
项目摘要
Share II的应用旨在探索控制珠蛋白基因的表观遗传机制
在红细胞生成过程中的调节。该项目的中心假设是miR-29b
逆转γ-珠蛋白向β-珠蛋白基因的转换并诱导HbF
甲基化。旨在诱导HBF表达的治疗性干预是一种有效的方法
用于改善成人和儿童镰状细胞病(SCD)的临床症状。
羟基脲是FDA批准的唯一一种已证明有效的药物,可用于诱导慢性阻塞性肺疾病患者的HBF
SCD,但DNA甲基转移酶(DNMT)抑制剂已显示出作为HBF诱导剂的前景
产生近端γ-珠蛋白启动子dna低甲基化。然而,DNMT抑制剂可以
产生偏离目标的副作用。小的非编码microRNAs(MiR)是一种具有吸引力的分子
靶向抑制γ-珠蛋白基因表达的研究表明miR-29b抑制dna
通过直接靶向DNMT3a和Dnmt3b的3‘非翻译区进行甲基化。这个
本提案的目的是测试miR-29b作为HBF诱导剂的效果。我们出版的作品
表明miR-29b对重新激活γ-珠蛋白转录和Hbf表达是重要的
靶向参与γ甲基化和基因转录的已知DNA珠蛋白抑制因子MYB
沉默。为了检验我们的中心假设,我们将实现一个特定的目标来确定
MiR-29b介导人HBB基因座DNA甲基化表观遗传改变的能力
在成人红细胞生成过程中重新激活γ-珠蛋白转录和Hbf表达。分目标A意志
用体外原液探讨miR-29b对γ-珠蛋白调节的分子作用
分离的外周血单核细胞生成红系祖细胞的培养体系
来自SCD患者。这些发现将与正常的红系祖细胞进行比较以验证
MiR-29b通过近端启动子重新激活γ-珠蛋白转录的能力
甲基化。MiR-29b介导的脱靶效应将通过DNA突变和
RNA-SEQ分析。为了确定miR-29b在逆转红系祖细胞表型中的作用
将评估在低氧条件下的镰刀运动。次级目标B将确定最佳剂量
利用临床前Townes在体内介导γ珠蛋白重新激活和HbF诱导的MIR-29b
SCD小鼠模型。这项研究强调了一种新的基于miRNA的表观遗传学方法来诱导
HBF将影响新药的发现,以扩大SCD的治疗选择。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Athena Starlard-Davenport其他文献
Athena Starlard-Davenport的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 30.53万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 30.53万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 30.53万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 30.53万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 30.53万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 30.53万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 30.53万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 30.53万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 30.53万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 30.53万 - 项目类别: